What: MassBio’s 3rd Annual Equity, Diversity, and Inclusion (ED&I) Conference will bring together leaders in the life sciences from across Massachusetts to discuss the significance of diversity and inclusion of resources, experiences, and perspectives, and how this is fundamental to innovation. Through three sessions, expert panelists will share their insight on the importance of instilling and inspiring hope, meaning, belonging, and motivation consistently throughout the life sciences, how cultural norms and codes are developed, and how we can create lasting change as we move into the new normal caused by the COVID-19 pandemic.
When: Tuesday, August 18th, 2020 at 10:00 am – 12:15 PM.
Where: Due to the ongoing concern around the spread of COVID-19, and to ensure the health and safety of all participants, we will be hosting MassBio’s 3rd Annual ED&I Conference virtually via Zoom.
Who: MassBio President & CEO, Robert K. Coughlin will deliver the opening remarks. He will be joined by:
- Ann-Marie La Ronde-Richard, Ph.D., Steering Committee Member, The Color of Biotech; Founder, Dominican Health and Education Initiative; Patient and External Association Engagement Lead, Pfizer who will moderate a panel with Charlotte Jones-Burton, M.D., President & Founder, Women of Color in Pharma (WOCIP); Vice President of Global Clinical Development, Nephrology, Otsuka Pharmaceutical Cos. U.S. on race in the workplace
- Aman Khera, Global Head of Regulatory Strategy, Worldwide Clinical Trials who will participate on the panel, “Cross Cultural Solidarity in the Biotech Industry”
- Andrew Dobos, Head of Organization and Talent Development, Moderna, Sarah EchoHawk, President, American Indian Science & Engineering Society (AISES), and Jill Houghton, President & CEO, Disability:IN, who will participate on the panel, “Closing Discussion: Moving on to the Next Normal and How It Will Impact ED&I”
View the full agenda, here.
Interested media can register for free by contacting Jennifer Nason.
Sponsors of the event include: Acceleron, Biogen, Blueprint Medicines, EMD Serono, Novartis, Sage Therapeutics, Sanofi Genzyme, Takeda, and Vertex.